SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Synchronous OR metachronous occurrence of HL with NHL. Possible explanations 1) Both arise coincidentally from unrelated lymphoid elements 2) HL progresses from previous NHL 3) Both derive from common precursor cell
Previously, the term for this code was composite Hodgkin and non-Hodgkin lymphoma. In the 2008 WHO, the term used to describe this same disease is B-cell lymphoma, unclassifiable, with features indeterminate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. The change in terminology reflects current clinical knowledge that the non-Hodgkin portion of this lymphoma has proven to be a B-cell immunophenotype.
The most common presentation is a large anterior mediastinal mass with or without involvement of supraclavicular lymph nodes. Other peripheral lymph node groups are less commonly involved. There may be direct extension to the lung, spread to liver, spleen, or bone marrow. Non-lymphoid organs are rarely involved. The combination of classical Hodgkin lymphoma and mediastinal large B-cell lymphoma may occur as a composite lymphoma or the patient may present with CHL and relapse/recur as large B-cell lymphoma.
Preferred primary sites are listed for this disease in the primary site field; however, involvement in other sites is possible, but rare. If you have confirmation that the only involved site is something other than the preferred primary listed, then code to that primary site.